Skip to content

CFDs are complex financial instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money. CFDs are complex financial instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

Why the Challenger share price crashed on Tuesday

We examine why the investment management firm saw its stock sold off sharply on Tuesday.

Why the Challenger share price crashed on Tuesday Source: Bloomberg

The Challenger share price crashed on Tuesday after the company released, what was received as a lacklustre Q3 trading update.

Company profile: Challenger Limited (ticker: CGF) is an investment management firm, with assets under management in excess of $100 billion. The firm is the largest provider of annuities in Australia.

Investors look to be disappointed by Challenger’s pre-tax, FY21 profit guidance, which is now forecast to come in at the lower end of the previously guided $390 million to $440 million range.

Management attributed this expected profit performance to weaker credit spreads in FY21, which according to the firm, ‘is not fully reflected in customer pricing’.

As a result of this, Challenger said it would respond by ‘significantly adjusting annuity pricing.’

For those reading the fine print, investors may have been concerned that Challenger will undershoot its new, more moderated expectations. Footnote 7 of the Q3 release noted:

‘The covid-19 situation and its impact on markets create an inherently uncertain environment. This could, among other things, impact the speed of deployment of Life’s capital and therefore impact guidance.’

Challenger Share Price Falls

By 1:31 PM the Challenger share price was down 14.09%, to $5.67 per share, as investors sold-down the stock heavily. CGF closed out the session down 15.76%.

This marks a distinct reversal for the stock, with CGF up a little over 40% before the Q3 announcement hit.

Despite this sell-off, analysts from Macquarie reiterated their Neutral rating and $6.30 price target on the stock, while saying:

‘We continue to like the long-term growth thematic, coupled with the capital benefits of the acquisition of the bank licence, however at present valuation looks fair.’

Other Points of Interest

Mind you, while the market responded poorly to this guidance, the Q3 trading update highlighted a number of positive developments.

Chief among them was Challenger’s assets under management, which rose 8% in the quarter to move past $100 billion for the first time.

This, said the firm, was driven by ‘Life annuity book growth' as well as 'a continuation of market leading Funds Management net flows.'

Specifically, Life's net flows in Q3 came in at $1,377 million, notching up record book growth of 9.2% in the process.

Total Life sales were $2,419 million (+155%), while total annuity sales came in at $979 million (+165%). Annuity sales growth, management said, was driven by 'strong growth in domestic term annuity sales' but 'partially offset by a moderation in the contribution from Japan.'

Secondly, looking at Challenger’s funds under management, the firm reported healthy growth driven by $7.0 billion in net flows and buoyant market conditions. Challenger’s FUM currently stands at $99.7 billion.

Want to trade Challenger long or short?

Open an account with us or login into your existing account to get started now.


This information has been prepared by IG, a trading name of IG Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.
CFDs are a leveraged products. CFD trading may not be suitable for everyone and can result in losses that exceed your initial deposit, so please ensure that you fully understand the risks involved.

Live prices on most popular markets

  • Forex
  • Shares
  • Indices

Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.

Plan your trading week

Get the week’s market-moving news sent directly to your inbox every Friday. The Week Ahead gives you a full calendar of upcoming economic events, as well as commentary from our expert analysts on the key markets to watch.

For more info on how we might use your data, see our privacy notice and access policy and privacy webpage.

You might be interested in…

Find out what charges your trades could incur with our transparent fee structure.

Discover why so many clients choose us, and what makes us a world-leading provider of CFDs.

Stay on top of upcoming market-moving events with our customisable economic calendar.